

The 2nd International Symposium of Clinical Immunology

Program

Friday 19 May 2023

Opening Address

9:00-9:10

Tomohiro Morio (President of the 2nd International Symposium of Clinical Immunology)

Morning Seminar 1

9:10-10:00

Sponsored by MIYARISAN Pharmaceutical CO. LTD

Chair Katsuyoshi Matsuoka (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan)

M1 Pathogenic oral-gut axis in inflammatory bowel disease

Nobuhiko Kamada (Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA)

Symposium 1

10:10-12:40

Recent Progress in the Treatment of Tissue Specific Immunological Diseases

Chairs Naoko Okiyama (Tokyo Medical and Dental University, Japan)

Yohei Mikami (Keio University School of Medicine, Japan)

S1-1 Central tolerance and type 1 diabetes

Mark S Anderson (Diabetes Center, University of California, San Francisco, San Francisco, USA)

S1-2 Recent progress in the treatment of psoriasis

Yukie Yamaguchi (Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan)

S1-3 Recent progress in the treatment of multiple sclerosis

Sachiko Miyake (Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan)

S1-4 Progress in the treatment of inflammatory bowel disease

Ryuichi Okamoto (Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan)

S1-5 Innovation of adoptive cancer immunotherapy with a synthetic biology approach

Yuki Kagoya (Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan)

Luncheon Seminar 1

12:50-13:40

Sponsored by CSL Behring K.K.

Chair Hirokazu Kanegae (Tokyo Medical and Dental University, Japan)

L1 Innovation and progress in the treatment of immunodeficiency with polyclonal immunoglobulin

Jordan S. Orange (Columbia University, USA)

Symposium 2

13:50-16:40

Immunological Basis of Human Disorders

Chairs Satoshi Okada (Hiroshima University, Japan)

Kensuke Miyake (The University of Tokyo, Japan)

Special Lecture S2-SP

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

Jean-Laurent Casanova (The Rockefeller University, New York, United States of America)

S2-1 Pathogenesis of immune disorders by dysregulation of the transcription factor function

Ichiro Taniuchi (Lab Transcriptional Regulation, RIKEN IMS, Yokohama, Japan)

S2-2 PYRIN inflames with CDC42

Takahiro Yasumi (Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan)

S2-3 Novel model mice of human inborn errors of immunity manifesting autoinflammation, autoimmunity and/or immunodeficiency

Tsuneyasu Kaisho (Wakayama Medical University, Wakayama, Japan)

S2-4 Immune disorders due to lysosomal nucleic acid stress

Kensuke Miyake (The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

S2-5 Regulation of phospholipid distribution in the lipid bilayer by flippases and scramblases

Shigekazu Nagata (Immunology Frontier Research Center, Osaka University, Osaka, Japan)

S2-6 Regulatory T cells in autoimmune disorders

Shimon Sakaguchi (Immunology Frontier Research Center, Osaka, Japan)

Sponsored by Pharming Group N.V.

Chair Ewen Munro (Pharming Group N.V., The Netherlands)

E1 Understanding APDS: Challenges in Diagnosis and Management

Andrew Cant (Consultant Paediatric Immunologist, Past ESID President, Newcastle-upon Tyne, UK)

Japanese focus on APDS

Akifumi Endo (Tokyo Medical and Dental University, Tokyo, Japan)

Poster Session

17:50-18:50

P-1 Identification of a novel inherited immunodysregulatory disorder caused by loss-of-function mutations in DExD/H box helicase SBNO2 and its molecular pathogenesis

Kazuyuki Meguro (Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, USA)

P-2 Clinical and genetic characteristics of IL10RA deficiency patients in Japan

Dan Tomomasa (Tokyo Medical and Dental University, Tokyo, Japan)

P-3 LIG4 syndrome mutation can lead to Th1-skewing intestinal inflammation in mice

Shinobu Tamura (Department of Emergency and Critical Care Medicine, Wakayama Medical University, Wakayama, Japan)

P-4 Clinical significance of serum cytokine profiling for the differentiation of underlying diseases in cytokine storm syndrome

Shuya Kaneko (Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan)

P-5 Transcriptome analysis of factors that prolong IgG4-related sialadenitis

Masaaki Uehara (Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

P-6 T follicular helper cells in blood mirror salivary gland-infiltrating T cells in primary Sjögren's syndrome (pSS)

Saori Abe (Department of Rheumatology, University of Tsukuba, Tsukuba, Ibaraki, Japan)

P-7 Analysis of peripheral blood samples from patients with systemic lupus erythematosus

Shuji Sumitomo (Department of Rheumatology, Kobe City Medical Center General Hospital, Kobe, Japan)

P-8 Immunophenotyping-Based Stratification of Mixed Connective Tissue Disease: Advancing Understanding of Heterogeneity by machine learning models
Shinji Izuka (Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)

P-9 Brain magnetic resonance vessel wall imaging in patients with neuropsychiatric systemic lupus erythematosus: A preliminary study
Masato Tarumi (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan)

P-10 Importance of trade-off strategy between glucocorticoids and immunosuppressants: Reduced rate of disease flares in Japanese patients with systemic lupus erythematosus
Chihiro Imaizumi (Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan)

P-11 The Efficacy of Mepolizumab against the Patients with Eosinophilic Granulomatosis with Polyangiitis as a Pilot Study
Tsuyoshi Kobashigawa (Division of Rheumatology, Department of 1st Comprehensive medicine, Saitama medical Center, Jichi Medical University, Saitama, Japan)

P-12 Titer of anti-nuclear matrix protein 2 antibody might reflect the disease activity of dermatomyositis/ polymyositis
Yuki Ichimura (Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan)

P-13 Idiopathic multicentric Castleman disease (iMCD-Nos) has been known as an abnormal immunoregulatory disorder
Kazuyuki Yoshizaki (SANKEN, Osaka University, Osaka, Japan)

P-14 Whole Body Fat Mass, Not BMI, Is the Risk for Crohn's Disease : A Mendelian Randomized Study
Ayako Fuchigami (Nippon Koukan Hospital, Kawasaki, Japan)

P-15 Obesity-related exacerbations of COVID-19 via accelerated cytokine responses
Seiya Oba (Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan)

P-16 Evaluation of protein expression and phosphorylation of SARS-CoV-2-infected placental tissue in the second trimester by tandem mass tag system
Kazuhide Takada (Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan)

P-17 Inhibition of FAS-mediated alveolar epithelial cell death suppresses lung injury and subsequent inflammasome activation in murine COVID-19 model.

Yoji Komiya (Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan)

P-18 Role of germinal center response in the antibody responses against SARS-CoV-2 spike protein

Jumana Khalil (Division of Molecular Pathology, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan)

P-19 A selective PPAR α modulator-mediated metabolic alteration ameliorates autoimmunity through restraining glutaminolysis in Th17 cells

Satoshi Masuyama (Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan)

P-20 Role of IL-21 in the maintenance and pathogenesis of murine Vg4 $^{+}$ IL-17-producing gamma-delta T cells

Yuki Hayashi (Department of Allergy and Clinical Immunology, Chiba University, Chiba, Japan)

P-21 Efficient strategy to capture eQTL heterogeneity using single-cell data

Masahiro Nakano (Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan)

P-22 TNF Receptor Associated Protein 1 (TRAP1) Variant Causing Respiratory Failure from Pneumocystis Carinii Pneumonia in non-HIV Patient

Louis Chai (Division of Infectious Diseases, National University Hospital, Singapore)

Saturday 20 May 2023

Morning Seminar 2

8:30-9:20

Sponsored by Mitsubishi Tanabe Pharma Corporation

Chair Hideto Kameda (Toho University, Japan)

M2 **Rheumatoid arthritis: advance in the management and our understanding on the synovial pathology orchestrated by TNFa**

Shinsuke Yasuda (Tokyo Medical and Dental University Hospital, Tokyo, Japan)

Sponsored Educational Seminar 1

9:30-10:10

Sponsored by Otsuka Pharmaceutical Co., Ltd.

Chairs Shinsuke Yasuda (Tokyo Medical and Dental University, Japan)

Masaki Shimizu (Tokyo Medical and Dental University, Japan)

ES1 **PLEASURE-J, a representative nationwide registry for patients with SLE**

Atsuko Murashima (National Center for Child Health and Development, Tokyo, Japan)

Symposium 3

10:10-12:10

Recent Progress in the Treatment of Systemic Immunological Diseases

Chairs Shinsuke Yasuda (Tokyo Medical and Dental University, Japan)

Masaki Shimizu (Tokyo Medical and Dental University, Japan)

S3-1 **Approach to cytokine storm syndromes in children: from macrophage activation syndrome (MAS) to multisystem inflammatory syndrome in children (MIS-C)**

Grant Schulert (Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, United States)

S3-2 **The Reality of Articular JIA in Japan and Challenges to Advancements in Treatment**

Takako Miyamae (Department of Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan)

S3-3 **Recent advances in the treatment of rheumatoid arthritis**

Yuko Kaneko (Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan)

S3-4 **ANCA-associated vasculitis and NETs**

Tatsuya Atsumi (Department of Rheumatology, Endocrinology and Nephrology, Hokkaido University, Sapporo, Japan)

Sponsored Educational Seminar 2

12:10-12:50

Sponsored by AstraZeneca K.K.

Chair Shinsuke Yasuda (Department of Rheumatology, Tokyo Medical and Dental University, Japan)

ES2 Recent progress in the treatment of systemic lupus erythematosus

Shingo Nakayamada (The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan)

Luncheon Seminar 2

13:00-13:50

Sponsored by Eli Lilly Japan K.K.

Chair Tatsuya Atsumi (Hokkaido University, Japan)

L2 Role for baricitinib in rheumatoid arthritis

Akio Morinobu (Kyoto University, Japan)

Symposium 4

14:00-16:30

Pathogenesis of Immunological Diseases

Chairs Keishi Fujio (The University of Tokyo, Japan)

Yukinori Okada (The University of Tokyo, Japan)

S4-1 Statistical genetics, disease biology, drug discovery, and personalized medicine

Yukinori Okada (Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan)

S4-2 An atlas of transcribed enhancers across immune cell diversity for decoding human immune-mediated diseases

Yasuhiro Murakawa (ASHBi Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan)

S4-3 Approaches for understanding the functions of genetic variants

Mineto Ota (Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan)

S4-4 Gene Regulatory Program Driving Dysfunctional Foxp3⁺ Regulatory T cells in Autoimmune Diseases

Tomokazu Sumida (Neurology, Yale School of Medicine, New Haven, United States)

S4-5 Intravital imaging-based single cell transcriptomics identifies novel pathogenic macrophage subsets in several diseases

Masaru Ishii (Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan)

Evening Seminar 2

16:40-17:30

Sponsored by Gilead Sciences K.K. and Eisai Co., Ltd.

Chair Yoshiya Tanaka (First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Fukuoka, Japan)

E2 The clinical efficacy and safety of a new-generation JAK inhibitor
"Filgotinib" in the treatment of rheumatoid arthritis.

Mitsumasa Kishimoto (Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan)

Closing Address

17:30-17:40

Tomohiro Morio (President of the 2nd International Symposium of Clinical Immunology)